Correlation Between F-FDG Uptake and Immune Cell Infiltration in Metastatic Brain Lesions

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Jul 12

PMID 34249674

Citations 4

Authors

Young-Sil An

Se-Hyuk Kim

Tae Hoon Roh

So Hyun Park

Tae-Gyu Kim

Jang-Hee Kim

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to investigate the correlation between F-fluorodeoxyglucose (FDG) uptake and infiltrating immune cells in metastatic brain lesions.

Methods: This retrospective study included 34 patients with metastatic brain lesions who underwent brain F-FDG positron emission tomography (PET)/computed tomography (CT) followed by surgery. F-FDG uptake ratio was calculated by dividing the standardized uptake value (SUV) of the metastatic brain lesion by the contralateral normal white matter uptake value. We investigated the clinicopathological characteristics of the patients and analyzed the correlation between F-FDG uptake and infiltration of various immune cells. In addition, we evaluated immune-expression levels of glucose transporter 1 (GLUT1), hexokinase 2 (HK2), and Ki-67 in metastatic brain lesions.

Results: The degree of F-FDG uptake of metastatic brain lesions was not significantly correlated with clinical parameters. There was no significant relationship between the F-FDG uptake and degree of immune cell infiltration in brain metastasis. Furthermore, other markers, such as GLUT1, HK2, and Ki-67, were not correlated with degree of F-FDG uptake. In metastatic brain lesions that originated from breast cancer, a higher degree of F-FDG uptake was observed in those with high expression of CD68.

Conclusions: In metastatic brain lesions, the degree of F-FDG uptake was not significantly associated with infiltration of immune cells. The F-FDG uptake of metastatic brain lesions from breast cancer, however, might be associated with macrophage activity.

Citing Articles

Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0.

Verger A, Tolboom N, Cicone F, Chang S, Furtner J, Galldiks N Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39762634 DOI: 10.1007/s00259-024-07038-5.

Immune checkpoint inhibition: a future guided by radiology.

Khan F, Jones K, Lyon P Br J Radiol. 2023; 96(1147):20220565.

PMID: 36752570 PMC: 10321249. DOI: 10.1259/bjr.20220565.

Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors.

Cohen I, Pareja F, Socci N, Shen R, Doane A, Schwartz J Front Immunol. 2022; 13:880959.

PMID: 36505421 PMC: 9731115. DOI: 10.3389/fimmu.2022.880959.

A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity Against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma.

Yang H, Zhang M, Sun H, Chai Y, Li X, Jiang Q Front Oncol. 2021; 11:783194.

PMID: 34869036 PMC: 8636331. DOI: 10.3389/fonc.2021.783194.

References

Gauci M, Lanoy E, Champiat S, Caramella C, Ammari S, Aspeslagh S . Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clin Cancer Res. 2018; 25(3):946-956. DOI: 10.1158/1078-0432.CCR-18-0793. View

Jamar F, Buscombe J, Chiti A, Christian P, Delbeke D, Donohoe K . EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013; 54(4):647-58. DOI: 10.2967/jnumed.112.112524. View

Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E . Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging. 2017; 44(13):2310-2325. DOI: 10.1007/s00259-017-3802-5. View

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino G . Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016; 43(11):1954-61. DOI: 10.1007/s00259-016-3425-2. View

Mazzaschi G, Madeddu D, Falco A, Bocchialini G, Goldoni M, Sogni F . Low PD-1 Expression in Cytotoxic CD8 Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. Clin Cancer Res. 2017; 24(2):407-419. DOI: 10.1158/1078-0432.CCR-17-2156. View

Pukrop T, Dehghani F, Chuang H, Lohaus R, Bayanga K, Heermann S . Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia. 2010; 58(12):1477-89. DOI: 10.1002/glia.21022. View

Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y . [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005; 7(4):369-79. PMC: 1501150. DOI: 10.1593/neo.04577. View

Lee S, Choi S, Kim S, Yun M, Kim H . Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses. J Gastric Cancer. 2018; 17(4):384-393. PMC: 5746659. DOI: 10.5230/jgc.2017.17.e43. View

Galdiero M, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S . Tumor associated macrophages and neutrophils in cancer. Immunobiology. 2013; 218(11):1402-10. DOI: 10.1016/j.imbio.2013.06.003. View

10.

Cacho-Diaz B, Garcia-Botello D, Wegman-Ostrosky T, Reyes-Soto G, Ortiz-Sanchez E, Herrera-Montalvo L . Tumor microenvironment differences between primary tumor and brain metastases. J Transl Med. 2020; 18(1):1. PMC: 6941297. DOI: 10.1186/s12967-019-02189-8. View

11.

Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T . New insight on the correlation of metabolic status on F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2019; 47(5):1127-1136. DOI: 10.1007/s00259-019-04500-7. View

12.

You H, Baluszek S, Kaminska B . Immune Microenvironment of Brain Metastases-Are Microglia and Other Brain Macrophages Little Helpers?. Front Immunol. 2019; 10:1941. PMC: 6710386. DOI: 10.3389/fimmu.2019.01941. View

13.

Ben-Haim S, Ell P . 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med. 2009; 50(1):88-99. DOI: 10.2967/jnumed.108.054205. View

14.

Tomita M, Suzuki M, Kono Y, Nakajima K, Matsuda T, Kuge Y . Influence on [F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor. EJNMMI Res. 2020; 10(1):24. PMC: 7080890. DOI: 10.1186/s13550-020-0608-4. View

15.

Cagney D, Martin A, Catalano P, Redig A, Lin N, Lee E . Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017; 19(11):1511-1521. PMC: 5737512. DOI: 10.1093/neuonc/nox077. View

16.

Kajary K, Lengyel Z, Tokes A, Kulka J, Dank M, Tokes T . Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations. Pathol Oncol Res. 2019; 26(2):997-1006. PMC: 7242263. DOI: 10.1007/s12253-019-00641-0. View

17.

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

18.

Deng S, Zhang W, Zhang B, Chen Y, Li J, Wu Y . Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis. PLoS One. 2015; 10(6):e0129028. PMC: 4454667. DOI: 10.1371/journal.pone.0129028. View

19.

Farber S, Tsvankin V, Narloch J, Kim G, Salama A, Vlahovic G . Embracing rejection: Immunologic trends in brain metastasis. Oncoimmunology. 2016; 5(7):e1172153. PMC: 5006920. DOI: 10.1080/2162402X.2016.1172153. View

20.

Horne Z, Jack R, Gray Z, Siegfried J, Wilson D, Yousem S . Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res. 2011; 171(1):1-5. DOI: 10.1016/j.jss.2011.03.068. View